Abstract:Secondary metabolites belonging to polyketide and nonribosomal peptide families constitute a major class of natural products with diverse biological functions and a variety of pharmaceutically important properties. Experimental studies have shown that the biosynthetic machinery for polyketide and nonribosomal peptides involves multi-functional megasynthases like Polyketide Synthases (PKSs) and nonribosomal peptide synthetases (NRPSs) which utilize a thiotemplate mechanism similar to that for fatty acid biosynthesis. Availability of complete genome sequences for an increasing number of microbial organisms has provided opportunities for using in silico genome mining to decipher the secondary metabolite natural product repertoire encoded by these organisms. Therefore, in recent years there have been major advances in development of computational methods which can analyze genome sequences to identify genes involved in secondary metabolite biosynthesis and help in deciphering the putative chemical structures of their biosynthetic products based on analysis of the sequence and structural features of the proteins encoded by these genes. These computational methods for deciphering the secondary metabolite biosynthetic code essentially involve identification of various catalytic domains present in this PKS/NRPS family of enzymes; a prediction of various reactions in these enzymatic domains and their substrate specificities and also precise identification of the order in which these domains would catalyze various biosynthetic steps. Structural bioinformatics analysis of known secondary metabolite biosynthetic clusters has helped in formulation of predictive rules for deciphering domain organization, substrate specificity, and order of substrate channeling. In this chapter, the progress in development of various computational methods is discussed by different research groups, and specifically, the utility in identification of novel metabolites by genome mining and rational design of natural product analogs by biosynthetic engineering studies.

Bioactive Natural Products Identification Using Automation of Molecular Networking Software

MS/MS-Based Molecular Networking: An Efficient Approach for Natural Products Dereplication

Computational Methods for Identification of Novel Secondary Metabolite Biosynthetic Pathways by Genome Analysis

Computational Tools for Discovering and Engineering Natural Product Biosynthetic Pathways

Focused Natural Product Elucidation by Prioritizing High-Throughput Metabolomic Studies with Machine Learning

Looking for Actives in the Haystack: Merging HRMS2-Based Molecular Networking, Chemometrics, and 13C NMR-Based Dereplication Approaches

High-Throughput Functional Annotation of Natural Products by Integrated Activity Profiling

Molecular networking as a dereplication strategy for monitoring metabolites of natural product treated cancer cells

Current and emerging tools and strategies for the identification of bioactive natural products in complex mixtures

Profiling Chemobiological Connection between Natural Product and Target Space Based on Systematic Analysis

Virtual Screening on Natural Products for Discovering Active Compounds and Target Information

Predicting biological activity from biosynthetic gene clusters using neural networks

Unraveling the Molecular Targets of Natural Products: Insights from Genomic and Proteomic Analyses

Artificial intelligence for natural product drug discovery

Use of Natural Products As Chemical Library for Drug Discovery and Network Pharmacology

High-Throughput Mining of Novel Compounds from Known Microbes: A Boost to Natural Product Screening

Annotation of natural product compound families using molecular networking topology and structural similarity fingerprinting

A Sample-Centric and Knowledge-Driven Computational Framework for Natural Products Drug Discovery

Discovering new bioactive molecules from microbial sources

Visualizing and Analyzing the Chemical Space of Natural Product Databases for Drug Discovery

The re-emergence of natural products for drug discovery in the genomics era